Coen Steven P. 4

What Happened

• Coen Steven P., Chief Financial Officer of Ginkgo Bioworks (DNA), had restricted stock units convert to common shares and disposed of shares tied to that vesting. On 2026-04-16 he converted two derivatives (587 and 156 RSUs, total 743 RSUs) into shares. Portions of those vested shares were sold to cover tax withholding. On 2026-04-17 he sold 324 shares in an open-market transaction at $7.95 per share, receiving $2,576.

Key Details

• Transaction dates and prices:
  • 2026-04-16: Conversion/exercise of 587 RSUs and 156 RSUs (total 743) — exercise/conversion price not reported (derivative to common stock).
  • 2026-04-16: Corresponding disposals of those derivative shares to cover tax withholding (amounts and prices for sell-to-cover not disclosed).
  • 2026-04-17: Open-market sale of 324 shares at $7.95 each for $2,576.
• Shares owned after the transactions: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Each RSU converts into one share of Class A common stock.
  • F2: Some shares were sold to satisfy tax withholding (sell-to-cover); these are not discretionary sales.
  • F3/F4: The RSUs have multi-step vesting schedules (initial vest on May 1, 2024, then monthly installments).
• Filing: Report filed 2026-04-20 covering the 2026-04-16 transaction date.

Context

• These transactions reflect RSU vesting and routine sell-to-cover tax withholding rather than an outright market-timed sale. The April 17 open-market sale of 324 shares is a small-dollar disposition ($2.6k) and may simply reflect liquidity needs tied to vesting rather than a broader statement of sentiment.